{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:54:43Z","timestamp":1792083283245,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,7,19]],"date-time":"2005-07-19T00:00:00Z","timestamp":1121731200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1038\/sj.bjc.6602703","type":"journal-article","created":{"date-parts":[[2005,7,28]],"date-time":"2005-07-28T21:34:32Z","timestamp":1122586472000},"page":"287-292","source":"Crossref","is-referenced-by-count":264,"title":["Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers"],"prefix":"10.1038","volume":"93","author":[{"given":"T C","family":"van Sprundel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M K","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Rookus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Brohet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C J","family":"van Asperen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E J Th","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L J","family":"van\u2018t Veer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A E M","family":"Tollenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,7,19]]},"reference":[{"key":"BF6602703_CR1","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1002\/1097-0142(19851015)56:8<2092::AID-CNCR2820560835>3.0.CO;2-7","volume":"56","author":"DE Anderson","year":"1985","unstructured":"Anderson DE, Badzioch MD (1985) Bilaterality in familial breast cancer patients. Cancer 56: 2092\u20132098","journal-title":"Cancer"},{"key":"BF6602703_CR2","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117\u20131130","journal-title":"Am J Hum Genet"},{"key":"BF6602703_CR3","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group (2001) Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 4, CD000487.doi:10.1002\/14651858.CD000487","DOI":"10.1002\/14651858.CD000487"},{"key":"BF6602703_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ajmg.1320560305","volume":"56","author":"DF Easton","year":"1995","unstructured":"Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265\u2013271","journal-title":"Am J Hum Genet"},{"key":"BF6602703_CR5","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/1097-0142(19840201)53:3+<712::AID-CNCR2820531320>3.0.CO;2-I","volume":"53","author":"ER Fisher","year":"1984","unstructured":"Fisher ER, Sass R, Fisher B (1984) Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure. Cancer 53: 712\u2013723","journal-title":"Cancer"},{"key":"BF6602703_CR6","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1086\/301749","volume":"62","author":"D Ford","year":"1998","unstructured":"Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676\u2013689","journal-title":"Am J Hum Genet"},{"key":"BF6602703_CR7","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa020119","volume":"346","author":"ND Kauff","year":"2002","unstructured":"Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609\u20131615","journal-title":"N Engl J Med"},{"key":"BF6602703_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/jnci\/95.13.941","volume":"95","author":"H Klaren","year":"2003","unstructured":"Klaren H, Van't Veer L, van Leeuwen F, Rookus M (2003) Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst 95: 941","journal-title":"J Natl Cancer Inst"},{"key":"BF6602703_CR9","doi-asserted-by":"crossref","unstructured":"Lostumbo L, Carbine N, Wallace J, Ezzo J (2004) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 3, CD002748.pub2.doi:10.1002\/14651858.CD002748.pub2","DOI":"10.1002\/14651858.CD002748.pub2"},{"key":"BF6602703_CR10","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1200\/JCO.2001.19.19.3938","volume":"19","author":"SK McDonnell","year":"2001","unstructured":"McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH, Johnson JL, Sitta DL, Slezak JM, Crotty TB, Jenkins RB, Sellers TA, Hartmann LC (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19: 3938\u20133943","journal-title":"J Clin Oncol"},{"key":"BF6602703_CR11","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","volume":"356","author":"SA Narod","year":"2000","unstructured":"Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, los Rios P, Weber B, Lynch H (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case\u2013control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356: 1876\u20131881","journal-title":"Lancet"},{"key":"BF6602703_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0002-9610(00)00505-5","volume":"180","author":"E Peralta","year":"2000","unstructured":"Peralta E, Ellenhorn J, Wagman L, Dagis A, Andersen J, Chu D (2000) Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180: 439\u2013445","journal-title":"Am J Surg"},{"key":"BF6602703_CR13","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"TR Rebbeck","year":"2002","unstructured":"Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616\u20131622","journal-title":"N Engl J Med"},{"key":"BF6602703_CR14","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1200\/JCO.1998.16.5.1642","volume":"16","author":"M Robson","year":"1998","unstructured":"Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K (1998) BRCA-associated breast cancer in young women. J Clin Oncol 16: 1642\u20131649","journal-title":"J Clin Oncol"},{"key":"BF6602703_CR15","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1200\/JCO.2004.04.086","volume":"22","author":"M Schwartz","year":"2004","unstructured":"Schwartz M, Lerman C, Brogan B, Peshkin B, Hughes Halbert C, DeMarco T, Lawrence W, Main D, Finch C, Magnant C, Pennanen M, Tsangaris T, Willey S, Isaacs C (2004) Impact of BRCA1\/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22: 1823\u20131829","journal-title":"J Clin Oncol"},{"key":"BF6602703_CR16","doi-asserted-by":"crossref","unstructured":"The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91: 1310\u20131316","DOI":"10.1093\/jnci\/91.15.1310"},{"key":"BF6602703_CR17","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1200\/JCO.1999.17.11.3396","volume":"17","author":"LC Verhoog","year":"1999","unstructured":"Verhoog LC, Brekelmans CT, Seynaeve C, Dahmen G, van Geel AN, Bartels CC, Tilanus-Linthorst MM, Wagner A, Devilee P, Halley DJ, van den Ouweland AM, Meijers-Heijboer EJ, Klijn JG (1999) Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 17: 3396\u20133402","journal-title":"J Clin Oncol"},{"key":"BF6602703_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0140-6736(97)07065-7","volume":"351","author":"LC Verhoog","year":"1998","unstructured":"Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, van den Ouweland A, Devilee P, Meijers-Heijboer EJ, Klijn JG (1998) Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351: 316\u2013321","journal-title":"Lancet"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602703.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602703","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602703.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:17:24Z","timestamp":1684412244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,19]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["BF6602703"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602703","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,19]]}}}